Vaximm AG

VAXIMM is a private, clinical-stage biotechnology company dedicated to developing oral T-cell immunotherapies for cancer patients.VAXIMM's technology is based on a first-class oral T-cell activator, which uses modified attenuated bacteria that can be easily adapted to various cancer-related antigens.The company's leading candidate product, oral VXM01, activates killer T cells targeting the tumor vasculature and certain immunosuppressive cells, thereby increasing the infiltration of immune cells in solid tumors.VXM01 is currently under clinical development for several tumor types, including pancreatic cancer, colorectal cancer, and brain cancer.